NASDAQ:MACK

Merrimack Pharmaceuticals Stock Forecast, Price & News

$6.43
+0.02 (+0.31 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.37
$6.48
50-Day Range
$6.04
$7.77
52-Week Range
$3.06
$9.45
Volume10,707 shs
Average Volume22,964 shs
Market Capitalization$86.23 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
30 days | 90 days | 365 days | Advanced Chart
Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Merrimack Pharmaceuticals logo

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.08 out of 5 stars

Medical Sector

1053rd out of 2,099 stocks

Pharmaceutical Preparations Industry

502nd out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What stocks does MarketBeat like better than Merrimack Pharmaceuticals?

Wall Street analysts have given Merrimack Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merrimack Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Merrimack Pharmaceuticals
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.14.
View Merrimack Pharmaceuticals' earnings history
.

How has Merrimack Pharmaceuticals' stock price been impacted by COVID-19?

Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MACK shares have increased by 133.0% and is now trading at $6.43.
View which stocks have been most impacted by COVID-19
.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Shares of Merrimack Pharmaceuticals reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the following people:
  • Mr. Gary L. Crocker M.B.A., MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman (Age 69, Pay $74.5k)
  • Dr. Ulrik B. Nielsen, Co-Founder & Independent Director (Age 49, Pay $76.88k)
  • Dr. Anthony J. Sinskey Ph.D., Sc.D., Co-Founder and Scientific Advisor (Age 81)
  • Geoffrey Grande C.F.A., Sr. Director of Communications
  • Ms. Ellen K. Forest, Head of HR (Age 57)
  • Dr. Fazal R. Khan Ph.D., Sr. VP of Manufacturing (Age 71)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 52)
  • Mr. Timothy R. Surgenor, Sec. (Age 61)

Who are some of Merrimack Pharmaceuticals' key competitors?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (4.54%), Bronte Capital Management Pty Ltd. (4.11%), Dimensional Fund Advisors LP (3.87%), BlackRock Inc. (1.91%), Sepio Capital LP (1.63%) and Renaissance Technologies LLC (1.40%). Company insiders that own Merrimack Pharmaceuticals stock include Eric Andersen, Gary L Crocker, Jason Aryeh, Jfl Capital Management, Llc and Noah G Levy.
View institutional ownership trends for Merrimack Pharmaceuticals
.

Which major investors are selling Merrimack Pharmaceuticals stock?

MACK stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Merrimack Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Merrimack Pharmaceuticals stock?

MACK stock was purchased by a variety of institutional investors in the last quarter, including Sepio Capital LP, Bank of New York Mellon Corp, Bronte Capital Management Pty Ltd., Millennium Management LLC, Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Geode Capital Management LLC, and Mascoma Wealth Management LLC. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Eric Andersen, Gary L Crocker, Jason Aryeh, Jfl Capital Management, Llc, and Noah G Levy.
View insider buying and selling activity for Merrimack Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $6.43.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals has a market capitalization of $86.23 million.

How many employees does Merrimack Pharmaceuticals have?

Merrimack Pharmaceuticals employs 27 workers across the globe.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.

Where are Merrimack Pharmaceuticals' headquarters?

Merrimack Pharmaceuticals is headquartered at ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.